Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Amit Sanyal, MD: A Clinician’s Perspective

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement

Oct

06

Today In Oncology

Impact of Proton and Photon Therapy on HRQOL in Breast Cancer

Older Women With High-Risk Breast Cancer Addition of Adjuvant Chemotherapy to Hormone Therapy

Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer is Low

Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Advertisement

© 2025 HSP News Service, L.L.C.